Introduction
============

Gastric cancer is one of the most common types of malignant tumor, with gastric cancer-associated mortality accounting for 23.03% of all malignant tumors ([@b1-ol-0-0-9156]), which is second only to lung cancer and ranks first in digestive tract tumors ([@b2-ol-0-0-9156],[@b3-ol-0-0-9156]).

The early diagnosis of gastric cancer improves the prognosis and the postoperative 5-year survival rate of early gastric cancer (EGC) has been recorded at 90% ([@b4-ol-0-0-9156]). EGC refers to cancer with an invasion depth limited to the mucosa or mucosa and submucosa, regardless of metastasis in the lymph nodes ([@b5-ol-0-0-9156]). The median duration of EGC prior to mortality (i.e., the survival time post-diagnosis) is 44 months ([@b6-ol-0-0-9156]) and if early cancerous lesions in the stomach are identified during this period, the prognosis of patients may be improved. Therefore, the effects of increasing the detection rate of EGC require study ([@b7-ol-0-0-9156]).

On the basis of the Paris endoscopic classification ([@b8-ol-0-0-9156]) and according to the gross morphology of lesions, EGC is divided into three types: Protruded type (0--I), flat type (0--II) and depression type (0--III). According to the morphology, the 0--II type is divided into three subtypes: Superficial protruded type (0--IIA), flat type (0--IIB) and superficial depression type (0--IIC). Type III may be more easily identified by gastroscopy and cancer cells may be determined by performing biopsy of tissues. In the progressive stage, gastric cancer may be observed under a gastroscope and cancer cells may be easily determined by biopsy.

According to the staging method by Shinji *et al* ([@b9-ol-0-0-9156]), the ulcer course may be divided into three stages: Active (A), healing (H) and scarring (S). Furthermore, each stage may be divided into two phases to provide the following: A1, A2, H1, H2, S1 and S2.

A previous study identified that gastric ulcers are a gastric precancerous disease ([@b10-ol-0-0-9156]), but were primarily aimed at situations where gastric ulcers are difficult to heal. Some researchers believe that endoscopic follow-up of benign gastric ulcers is hypothesized to be of limited value; for instance, Thomopoulos *et al* ([@b11-ol-0-0-9156]) demonstrated that during the 6-year follow-up of 731 patients with benign gastric ulcers, no case of gastric cancer was identified. In addition, Bustamante *et al* ([@b12-ol-0-0-9156]) revealed that no gastric cancer case was identified in 289 patients with benign gastric ulcers. However, in our 10 years of clinical work, (Ma *et al*, unpublished data), gastric cancer was occasionally identified. In an experimental group of 232 cases of patients with gastric ulcers, in which 9 patients were diagnosed with cancer, 5 cases of gastric cancers were detected from the edges of ulcers at 1, 14, 18, 19 and 22 months later, respectively. In another 4 cases, gastric cancers were detected from the base of ulcers at 1, 6, 17 and 24 months later, respectively. By repeated gastroscopic biopsy of the healed gastric ulcer site and was diagnosed as EGC by surgery and pathology. Mañas *et al* ([@b13-ol-0-0-9156]) identified that 8/452 patients with benign gastric ulcers were diagnosed with gastric cancer (detection rate, 1.8%) during follow-up. Therefore, we hypothesized that for healed or currently healing chronic gastric ulcers, the biopsy of the ulcer base during gastroscopic follow-up may improve the diagnosis of EGC compared with the traditional method of the biopsy of gastric ulcer margins.

Patients diagnosed with benign gastric ulcer at the Endoscopy Center of the Affiliated Huaian Hospital of Xuzhou Medical University (Huai\'an, China), were randomly divided into two groups: An experimental group and a control group. Furthermore, the patients underwent regular gastroscopic rechecks to assess whether the biopsy of the ulcer margins and base may improve the detection rate of EGC compared with the biopsy of ulcer margins alone.

Patients and methods
====================

### Selection of subjects and criteria

The present study was approved by the Ethics Committee of the Affiliated Huaian Hospital of Xuzhou Medical University and all patients provided written informed consent. Between January 1999 and December 2002 14, 202 patients ([Fig. 1](#f1-ol-0-0-9156){ref-type="fig"}) underwent gastroscopic examinations in the Endoscopy Center and gastric ulcer patients were rechecked at least twice by gastroscopy. Patients were followed-up for between 1 week and 24 months. A total of 281 patients were selected as controls and these patients underwent biopsy of the ulcer margins only. Following diagnosis with a benign ulcer, patients underwent 8 weeks of regular medical treatment and gastroscopic recheck started from the second week. If the ulcer began to heal, biopsy was no longer conducted. If the ulcer did not heal, only a biopsy of the ulcer margins was conducted. Between January 2006 and December 2009 and between March 2012 and December 2013, 28,142 patients ([Fig. 1](#f1-ol-0-0-9156){ref-type="fig"}) underwent gastroscopic examinations in the Endoscopy Center. Gastric ulcer patients were rechecked at least three times by gastroscopy and were followed up for between 1 week and 24 months. A total of 243 patients from this period were included in the experimental group, 11 of whom were lost to follow-up, and so 232 patients completed the study. Patients in the experimental group underwent biopsy of the ulcer margins. When diagnosed with a benign ulcer, patients underwent 8 weeks of regular medical treatment and gastroscopic recheck began from the second week. If the ulcer healed, only biopsy of the ulcer margins was conducted; however, if the ulcer healed or was currently healing, biopsy of the ulcer base was conducted. Clinical, endoscopic and pathological examination data were collected from the two groups of patients. During the last 4 weeks prior to gastroscopic examination, all patients did not use proton pump inhibitors, Bismuth agents, H~2~ receptor antagonists or antibiotics.

### Tissue samples

All 513 selected patients (281 patients in the control group and 232 patients in the experimental group) underwent regular gastroscopic biopsy. Patients in the control group underwent biopsy of the ulcer margins only. Patients in the experimental group underwent a biopsy of the ulcer margins during the active stage of the ulcer, and a biopsy of the ulcer margins and base if the ulcer healed or was currently healing. Between 4 and 6 sections of biopsy samples were obtained using disposable biopsy forceps, and were sent to the Department of Pathology of The Affiliated Huaian Hospital of Xuzhou Medical University for histopathological diagnosis. The gastroscopy and biopsy records of all patients were complete.

### Exclusion criteria of disease cases

Patients with the following were excluded: Acute erosive gastritis, cancerous ulcers, compound ulcers and multiple gastric ulcers; patients diagnosed with benign ulcers by visual observation, but diagnosed with gastric cancer during the initial biopsy; and patients with gastric ulcers occurring after gastric cancer surgery.

### Research methods

The epidemiological features of patients included the following: Sex, age, smoking history and the administration of non-steroidal anti-inflammatory drugs (NSAIDs).

### Investigation method of the administration history of NSAIDs

Regardless of dose and duration, the oral administration of NSAIDs prior to gastroscopic examination was defined as the administration of NSAIDs.

### Helicobacter pylori detection using rapid urease

The white square silicone oil slip sheet of the *H. pylori* test paper was removed and biopsy samples were placed in the center of the round yellow paper. Subsequently, the adhesive paper was fixed on the plastic in order to fix the test paper with biopsy tissues to the plastic. The results were observed under normal temperature conditions. The alteration in the color of the margins of the biopsy tissue on the test paper determined the judgment criteria, as follows: Strong positive result, yellow to red within 1 min; weak positive result, yellow to red within 3 min; and negative result, no change. The outcome was invalid if a change occurred after 3 min.

### Helicobacter pylori detection by ^13^C expiration

The investigation was performed on patients either in the morning, when stomach was empty, or following \>2 h fasting. Patients filled out the required information on the two labeled air bags and subsequently blew air into the bags in a normal manner until the bags were full. The bag covers were then immediately tightened. The air collected was defined as the '0-min expiration air'. The subjects took one urea ^13^C capsule with between 80 and 100 ml cold drinking water and sat quietly. After 30 min, expiration air was collected from the subjects as aforementioned, and the air collected was defined as the '30-min expiration air'. '0-min expiration air' and '30-min expiration air' were used for ^13^CO~2~ detection, with δ‰ (parts/thousand) used to represent the results. The following formula was used: δ‰=(^13^C abundancedetermined sample-^13^C abundancereference sample) ×1000/^13^C abundancereference sample. The diagnosis of *H. pylori* was determined on the basis of the difference between the δ‰ values of the '0-min expiration air' minus and that of the '30-min expiration air' (detection value=δ‰ at 30 min-δ‰ at 0 min). When the positive judgment value was ≥4.0±0.4 (mean ± standard deviation), subjects were defined as *H. pylori*-positive.

### Judgment criteria of H. pylori infection

When the urease and ^13^C expiration tests presented positive results, or when urease was negative and ^13^C was positive, the patient was identified as infected with *H. pylori*. If the urease and ^13^C expiration tests presented negative results, or if the urease test was positive and ^13^C expiration test was negative, the patient was identified to be negative for *H. pylori*.

### Medical treatment scheme for gastric ulcer

Treatment for *H. pylori*-positive gastric ulcers was as follows: Rabeprazole sodium enteric-coated capsules, 20 mg, twice/day for 14 days; colloidal bismuth pectin dry suspension, 150 mg, three times/day for 14 days; clarithromycin sustained-release tablets, 500 mg, twice/day for 14 days; and amoxicillin, 1,000 mg, twice/day for 14 days. After 14 days of treatment, clarithromycin sustained-release tablets and amoxicillin were ceased, and the administration of rabeprazole sodium enteric-coated capsules and colloidal bismuth pectin dry suspension was continued for 6 weeks. Treatment for *H. pylori*-negative gastric ulcers was as follows: Rabeprazole sodium enteric-coated capsules, 20 mg per day for 8 weeks; and colloidal bismuth pectin dry suspension, 150 mg, three times/day for 8 weeks

### Gastroscopy

All patients were examined using the Olympus GIF-XQ240 and GI-XQ260 series electronic gastroscope (Olympus Corporation, Tokyo, Japan) and all examinations were completed by two experienced endoscopic physicians.

### Preparation prior to the examination

All patients were examined with an empty stomach in the early morning. A total of 10 mg racanisodamine hydrochloride was intramuscularly injected 5 min prior to the examination. Subsequently, 1 bottle of dyclonine hydrochloride mucilage was orally taken (0.1 g, 10 ml).

### Examination steps

A conventional endoscope was inserted and reached the descending part of the duodenum, and the pyloric canal, gastric antrum, gastric body and gastric fundus were observed during the withdrawal of the gastroscope. If suspected lesions were identified, lesion morphology, margins and color distinctions of the surrounding area were preliminarily observed and images were acquired. The majority of benign ulcers were round or elliptical, although certain ulcers were linear with smooth margins. The bottom was covered with yellowish gray or grayish white exudate, the surrounding mucosa presented with congestion and edema, and the plicae around the ulcer were centrally located. Biopsy tissues were obtained from a number of lesion sites using disposable biopsy forceps for pathological examination.

### Sampling

Patients in the control group underwent biopsy of the ulcer margins only. When diagnosed with a benign ulcer, patients underwent 8 weeks of regular medical treatment with gastroscopic recheck beginning from the second week. If the ulcer began to heal, biopsy was no longer conducted; however, if the ulcer did not heal, biopsy of the ulcer margins was conducted. The duration of follow-up by gastroscopy ranged between 1 week and 24 months. Patients in the experimental group underwent biopsy of the ulcer margins alone in the initial gastroscopy, and following diagnosis with a benign ulcer, the patients underwent 8 weeks of regular medical treatment, with gastroscopic recheck beginning from the second week. During the healing process of the ulcer, the ulcer margins were prioritized as the site of gastroscopic biopsy. If the ulcers healed or were currently healing, biopsy samples were obtained from the ulcer base or the healed sites. Gastroscopy rechecks in the experimental group were conducted on weeks 2, 4 and 8, and thereafter once a year. When gastric cancer was identified, patients were surgically treated, followed by gross histopathological examination. From each ulcer lesion, between 4 and 6 biopsy samples were obtained.

### Pathological examination

All biopsy samples were placed on filter paper, fixed in 10% formalin solution and sent to the Department of Pathology of The Affiliated Huaian Hospital of Xuzhou Medical University (Huai\'an, China) for histopathological diagnosis. All biopsies were conducted by experienced pathologists following fixation in 10% formalin solution, then dehydration, clearing, and infiltrating were finished in the machine overnight (12 h), embedding in paraffin (\~2 h at 58°C). Sections were sliced at a thickness of \~4 µm. Subsequently, sections were subjected to hematoxylin eosin staining: i) The sections were deparaffinized, flamed using a burner and then placed in the \>99% xylene. This step was repeated 2 times; ii) the tissues were hydrated by passing through decreasing concentrations of alcohol and water (100, 90, 80 and 70%); iii) the sections were stained in hematoxylin (1 g) for 5 min at room temperature; iv) and were then washed with tap water for ≤5 min, until a blue color change was observed; v) excess dye was removed and the clear staining effect achieved following the addition of 1% acid alcohol (1% HCL in 70% alcohol) for 5 min; vi) and were then washed in running tap water until the sections were again blue by dipping in an alkaline solution followed by another tap water wash; vii) the sections were stained with 1% eosin for 10 min; viii) and were then washed in tap water for 5 min; ix) the sections were dehydrated in increasing concentrations (85, 90, 95, 10 and 100%) of alcohols and placed in \>99% xylene; and x) a neutral balsam neutral gum (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) was used to seal the sections.

### Statistical analysis

Data were recorded using Windows Excel (2007; Microsoft Corporation, Redmond, WA, USA) and analyzed using Stata for Windows (version 12.0; StataCorp LP, College Station, TX, USA). Data are expressed as the mean ± standard deviation and count data were expressed as percentages. Continuous variables, including age, were compared using Student\'s t-test and discrete variables were compared using the χ^2^ test. The inspection level was α=0.05 and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Epidemiological characteristics of patients in the two groups
-------------------------------------------------------------

### Sex and age

In the control group, 185/281 patients were male and 96/281 patients were female, with a male-to-female ratio of 1.93:1. The age of patients in the control group ranged between 30 and 80 years, with a mean age of 53.9±12.7 years. In the experimental group, 139/232 patients were male and 93/232 patients were female, with a male-to-female ratio of 1.49:1. The age of patients in the experimental group ranged between 30 and 83 years, with a mean age of 55.8±12.0 years.

### Previous medical history

In the control group, 89 patients (31.7%) exhibited a history of smoking, 87 patients (31.0%) possessed a history of NSAID administration, 149 patients (53.0%) had a *H. pylori*-positive history, and 45 patients (16.0%) had never smoked and never used NSAIDs. In the experimental group, 79 patients (34.1%) exhibited a history of smoking, 61 patients (26.3%) possessed a history of NSAID administration, 140 patients (60.3%) have a *H. pylori*-positive history, and 28 patients (12.1%) have never smoked and never used NSAIDs ([Fig. 2](#f2-ol-0-0-9156){ref-type="fig"}).

### Statistical analysis of epidemiological characteristics

Differences between the epidemiological characteristics of the two groups of patients were not identified to be statistically significant (P\>0.05; [Table I](#tI-ol-0-0-9156){ref-type="table"}).

### Gastric cancer cases determined in patients

In the experimental and control groups overall, 12 (2.34%) patients with a gastric ulcer were diagnosed with gastric cancer. Furthermore, gastric cancer was identified in 9 patients in the experimental group (detection rate, 3.88%), with 5 of these patients diagnosed with gastric cancer at 1, 14, 18, 19 and 22 months, respectively, following the diagnosis of gastric ulcer. Diagnoses were validated by biopsies obtained from the margins of the ulcer that had healed, or almost healed. The remaining 4 patients were diagnosed with gastric cancer at 1, 6, 17 and 24 months, respectively, following the diagnosis of the gastric ulcer, which was subsequently confirmed by biopsy of the base of the healed ulcers ([Table II](#tII-ol-0-0-9156){ref-type="table"}). All 9 patients with gastric cancer underwent surgical treatment and were validated as patients with EGC by postoperative pathology. In the control group, 3/281 patients were diagnosed with gastric cancer (detection rate, 1.07%) at 3, 15 and 16 months, respectively, following the diagnosis of gastric ulcer, and were validated by biopsy of the margins of the almost healed ulcers ([Table III](#tIII-ol-0-0-9156){ref-type="table"}). All 3 patients with gastric cancer underwent surgical treatment and were diagnosed with EGC by postoperative pathology.

### Statistical comparison of EGC cancer detection rate between the two groups

The detection rate of gastric cancer in patients in the experimental group and control group was 3.88 and 1.07%, respectively. The difference was identified to be statistically significant (P\<0.05; [Table IV](#tIV-ol-0-0-9156){ref-type="table"}).

### Comparison of H. pylori infection rate between patients with EGC and non-gastric cancer patients

A total of 12/513 patients with gastric ulcers in the two groups were diagnosed with EGC, with all 12 patients identified to be infected with *H. pylori* (infection rate, 100%). Among the gastric ulcer patients who were not diagnosed with gastric cancer, 277/501 patients were diagnosed with *H. pylori* infection (infection rate, 55.29%). The difference between the two groups was identified to be statistically significant (P\<0.05; [Table V](#tV-ol-0-0-9156){ref-type="table"}).

Discussion
==========

With the decreasing incidence of gastric cancer and the wide use of NSAIDs following identification of benign gastric ulcers by gastroscopic observation and biopsy pathology, the necessity of regular follow-ups by gastroscopy remains controversial in Western countries ([@b13-ol-0-0-9156]--[@b15-ol-0-0-9156]). A previous study revealed that in 144 patients with a benign gastric ulcer, \~7% patients were eventually diagnosed with gastric cancer ([@b16-ol-0-0-9156]). Todd *et al* ([@b17-ol-0-0-9156]) hypothesized that, if ulcers were diagnosed to be benign by endoscopic observation and were pathologically confirmed, all patients with gastric ulcer require follow-up by gastroscopy in order to assess ulcer healing and the occurrence of malignant transformation. Furthermore, the British Society of Gastroenterology guidelines ([@b18-ol-0-0-9156]) emphasize the value of follow-up by gastroscopy for patients with gastric ulcers. Eckardt *et al* ([@b19-ol-0-0-9156]) identified that 8/452 patients with benign gastric ulcers were diagnosed with gastric cancer (detection rate, 1.8%) during follow-up and demonstrated that regular follow-up by gastroscopy may improve the detection rate of EGC. Hopper *et al* ([@b20-ol-0-0-9156]) identified that follow-up by gastroscopy may enable earlier detection of gastric cancer, improving the survival time of patients with gastric cancer. In addition, Podolsky *et al* ([@b21-ol-0-0-9156]) revealed that 6 patients with gastric ulcers were diagnosed with gastric cancer during follow-up by gastroscopy and that 2 of these patients exhibited EGC, with lesions limited to the mucosa and submucosa and no lymph node metastasis. Furthermore, a previous study revealed that, despite the use of typical treatments (including the eradication of *H. pylori*), a number of patients with benign gastric ulcer exhibited disease progression and developed an ulcer with an undetermined nature, A limited number of these patients may have a gastric cancer type, including lymphoma ([@b22-ol-0-0-9156]).

It has been previously demonstrated that the likelihood of determining whether a benign ulcer will exhibit canceration during follow-up of patients is low; however, the cost-benefit ratio is high ([@b11-ol-0-0-9156],[@b12-ol-0-0-9156],[@b14-ol-0-0-9156]). Furthermore, a previous study identified patients to exhibit ulcer canceration during the follow-up, but their prognosis did not improve ([@b19-ol-0-0-9156]). In addition, a previous study revealed that it is inadequate to diagnose the nature of a disease only by visual inspection under an endoscope; therefore, biopsy is required ([@b23-ol-0-0-9156]). In previous studies, the detection rate of gastric cancer in gastric ulcer patients, according to gastroscopy and pathology during follow-up, was between 1.3 and 13.3% ([@b16-ol-0-0-9156],[@b24-ol-0-0-9156]). Therefore, it is necessary to perform regular gastroscopy on gastric ulcer patients in order to detect early canceration. A previous study revealed that gastric ulcers may heal as a result of effective anti-ulcer drug treatment ([@b5-ol-0-0-9156]). In addition, sampling from the base of the healed ulcer for biopsy may assist in detecting gastric cancer at an earlier stage ([@b25-ol-0-0-9156]). Banerjee *et al* ([@b26-ol-0-0-9156]) hypothesized that a biopsy was necessary after the ulcer healed, that samples may be obtained from the base of the ulcer, that patients may be followed up for \>1 year and that it was incorrect to consider a healed ulcer as a benign lesion. Additionally, Esmadi *et al* ([@b27-ol-0-0-9156]) hypothesized that gastric ulcers may be cured and demonstrated that patients should undergo regular gastroscopic recheck. Podolsky *et al* ([@b21-ol-0-0-9156]) identified that a biopsy of the healed sites of the gastric ulcer was required. However, to date, there have been no large-sample studies in which, following healing of a gastric ulcer, EGC has been determined using gastroscopy, pathological follow-up examinations and biopsies of the healed site.

In the present study, 513 patients with gastric ulcers were followed up for between 1 week and 24 months. In the experimental group, 9/232 patients developed EGC and *H. pylori* infection, with a gastric cancer detection rate of 3.88%, which was consistent with the results found by Ogura *et al* ([@b28-ol-0-0-9156]). Furthermore, after the ulcers had almost or completely healed, 9 cases of gastric cancer were determined by biopsy of the margins or base of the ulcer, and the detection rate of EGC was increased compared with that of the control group. The results of the present study suggested that the additional biopsy of the ulcer base during the healing process may improve the detection rate of EGC.

In the present study, the *H. pylori* infection rate was 56.3% and patients with EGC exhibited a significantly increased *H. pylori* infection rate compared with patients with gastric ulcers alone, suggesting that *H. pylori* infection is associated with gastric cancer. The results of the present study suggest that, under the same conditions of *H. pylori* infection, atrophic gastritis, intestinal metaplasia and atypical hyperplasia, gastric cancer may develop not only on the ulcer margins, but also on the ulcer base.

An endoscope with advanced auxiliary functions, including magnifying endoscopy, narrow-band imaging endoscopy, staining endoscopy, ultrasound endoscopy and confocal endomicroscopy, would enable the local mucosal structure and layer structures of tissues to be observed. Additionally, experience of gastroscopy technology and the endoscopic biopsy technique continues to increase, which may improve the detection rate of EGC. In the present study, the biopsy of the ulcer base is hypothesized to be of increased importance since it may be more effective and enable the detection of gastric cancer at an earlier stage. To the best of our knowledge, there are no studies on its underlying molecular mechanism of occurrence on a global scale. It is hypothesized that a gastric ulcer may occur on the basis of EGC. If the malignant degree of cancer cells is decreased, the invasion and damage effects of cancer cells are less than the proliferation effect of the cancerous tissue itself, however, if cancerous tissues are submucosal infiltrating growth, the ulcer may shrink and even completely heal. Therefore, early cancer lesions may be identified in healed gastric ulcers, which may explain clinical ulcer repair in type II and III gastric ulcers, but does not explain the occurrence of EGC in healed ulcer sites. However, the occurrence of early cancer lesions in the gastric ulcer healed sites may be due to the mutation of submucosal cells in the ulcer base. During the process of ulcer repair, cancer cells (EGC) gradually transition to the mucosal surface where, over time and following alterations in the internal and external environment, these cells progress to advanced gastric cancer. This hypothesis may explain EGC that is identified following the repair of large gastric ulcers.

In the experimental and control groups, 9/232 and 3/281 patients were diagnosed with EGC, respectively (detection rates, 3.88 and 1.07%, respectively), and the difference between the two groups was identified to be statistically significant. The results of the present study suggested that gastroscopy and pathological follow-up of chronic gastric ulcers, during and after the healing process, is required and is of greater importance in regions with an increased incidence of gastric cancer. In addition, biopsy of the base or margins of healing or healed ulcers in gastroscopic follow-ups is important. At present, in China, patients with chronic gastric ulcer may not fully understand the seriousness of ulcerated lesions. Clinicians may not realize the importance of gastroscopic biopsy and the biopsy site of healing or healed gastric ulcers. Therefore, additional studies on this topic and large-scale multicenter randomized controlled trials of chronic gastric ulcers are required.
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![Smoking, NSAID and *Helicobacter pylori* history of patients in control and experimental groups. NSAID, non-steroidal anti-inflammatory drugs; Hp, *Helicobacter pylori*.](ol-16-04-4211-g01){#f2-ol-0-0-9156}

###### 

Statistical analysis of epidemiological features between the experimental group and the control group.

  Feature                        Experimental group (n=232)                               Control group (n=281)   P-value
  ------------------------------ -------------------------------------------------------- ----------------------- ----------------------------------------------------
  Sex, n                                                                                                          
    Male                         139                                                      185                     0.167^[a](#tfn1-ol-0-0-9156){ref-type="table-fn"}^
    Female                       93                                                       96                      
  Mean age, years                55.8±12.0^[b](#tfn2-ol-0-0-9156){ref-type="table-fn"}^   53.9±12.7               0.080^[c](#tfn3-ol-0-0-9156){ref-type="table-fn"}^
  Smoking history, n                                                                                              
    Smoking                      79                                                       89                      0.568^[a](#tfn1-ol-0-0-9156){ref-type="table-fn"}^
    No smoking                   153                                                      192                     
  NSAID use, n                                                                                                    
    Yes                          61                                                       87                      0.245^[a](#tfn1-ol-0-0-9156){ref-type="table-fn"}^
    No                           171                                                      194                     
  Hp infection, n                                                                                                 
    Yes                          140                                                      149                     0.096^[a](#tfn1-ol-0-0-9156){ref-type="table-fn"}^
    No                           92                                                       132                     
  NSAID use without smoking, n                                                                                    
    Yes                          28                                                       45                      0.201^[a](#tfn1-ol-0-0-9156){ref-type="table-fn"}^
    No                           204                                                      236                     

χ^2^ test

mean ± standard deviation

Student\'s t-test. NSAID, non-steroidal anti-inflammatory drugs; Hp, *Helicobacter pylori*.

###### 

Clinical features of the 9 patients diagnosed with gastric cancer in the experimental group.

                                     Patient no.                                                              
  ---------------------------------- ------------- -------- ------ -------- -------- ------ -------- -------- ------
  Sex                                M             M        F      M        F        F      M        F        M
  Age, years                         65            57       48     70       63       49     56       67       55
  Hp infection                       Yes           Yes      Yes    Yes      Yes      Yes    Yes      Yes      Yes
  History of NSAIDs use              No            No       No     Yes      No       Yes    No       Yes      No
  Biopsy blocks, n                   5             4        6      5        4        4      6        7        5
  Gastric cancer location in ulcer   Base          Margin   Base   Margin   Margin   Base   Margin   Margin   Base

M, male; F, female; Hp, *Helicobacter pylori*; NSAIDs, non-steroidal anti-inflammatory drugs.

###### 

Clinical features of 3 patients diagnosed with gastric cancer in the control group.

                                     Patient no.            
  ---------------------------------- ------------- -------- --------
  Sex                                M             F        M
  Age, year                          63            55       61
  Hp infection                       Yes           Yes      Yes
  History of NSAIDs use              No            No       Yes
  Biopsy blocks, n                   5             4        6
  Gastric cancer location in ulcer   Margin        Margin   Margin

M, male; F, female; Hp, *Helicobacter pylori*; NSAIDs, non-steroidal anti-inflammatory drugs.

###### 

Comparison of gastric cancer detection rate between the control and experimental groups.

  Group          No. of positive gastric cancer cases   No. of negative gastric cancer cases   Total   Detection rate, %   P-value^[a](#tfn6-ol-0-0-9156){ref-type="table-fn"}^
  -------------- -------------------------------------- -------------------------------------- ------- ------------------- ------------------------------------------------------
  Experimental   9                                      223                                    232     3.88                0.034
  Control        3                                      278                                    281     1.07                

χ^2^ test; χ^2^=4.502.

###### 

Comparison of the *Helicobacter pylori* infection rate between patients with early gastric cancer and patients without gastric cancer.

  Patients                      No. of Hp positive cases   No. of Hp negative cases   Total   Hp-positive rate, %   P-value^[a](#tfn8-ol-0-0-9156){ref-type="table-fn"}^
  ----------------------------- -------------------------- -------------------------- ------- --------------------- ------------------------------------------------------
  Patients with EGC             12                         0                          12      100.0                 0.002
  Non-gastric cancer patients   277                        224                        501     55.29                 

χ^2^=9.524.

χ^2^ test; ECG, early gastric cancer; Hp, *Helicobacter pylori*.

[^1]: Contributed equally
